The Role
Senior Scientist/Principal Scientist, DMPK
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.
We are looking for a highly motivated and skilled DMPK Scientist with expertise in small molecule drug discovery and early development. Reporting to the Staff Scientist, DMPK, this role will represent the DMPK function on projects, guiding and implementing strategies and enabling timely data-driven decision-making throughout the life cycle of small molecule therapeutics. Key deliverables are human PK and efficacious dose predictions and clinical risk assessment based on translating in vitro and nonclinical data. This is an excellent opportunity to join a biotech company with groundbreaking work in the field. This role is onsite.
JOB RESPONSIBILITIES:
- Be a key contributor and subject matter expert to DMPK strategy from drug discovery through development and filing by acting on interdisciplinary project teams to identify and address ADME-centered matters for small molecule therapies
- Partner with medicinal chemistry to efficiently profile, optimize, and select small molecules with ADME properties fit to the therapeutic profile; accomplishing this through designing and integrating data from in silico, in vitro, and preclinical pharmacokinetic studies, and translating to predictions of human PK and PD
- Collaborate with nonclinical safety/toxicology and bioanalysis to guide dose selection and to characterize exposure-response to establish safety profile
- Act as a key member of pharmacology teams to guide study design and data interpretation for PK/PD and PK-biomarker relationships that support advancement of development candidate molecules
- Effectively communicate DMPK data and its interpretation for decision-making to project teams
- Manage and oversee external vendors for completing in vitro and in vivo studies
- Serve as a subject matter expert to write Nonclinical Pharmacology sections of regulatory (IND/CTA) filings, IB updates, and responses to regulatory queries
QUALIFICATIONS:
- MS or PhD in Drug Metabolism, Pharmacokinetics, Chemistry, or related scientific discipline with a minimum 5+ years of pharmaceutical drug discovery and development experience or BSc with 10+ years of experience
- Excellent critical thinking and scientific skills with proven scientific expertise in small molecule metabolism and pharmacokinetics
- Demonstrated success working effectively and collaboratively on cross-functional projects teams
- Excellent oral presentation and written communication skills
- $160,000-200,000 annual base salary
Tenvie is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit and business need.
Similar Jobs
Get Personalized Job Insights.
Our AI-powered fit analysis compares your resume with a job listing so you know if your skills & experience align.
Success! Refresh the page to see how your skills align with this role.
The Company
What We Do
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
